A 52-year-old man with newly diagnosed metastatic pancreatic cancer presents with swelling and erythema of the left calf. Doppler ultrasound confirms acute deep vein thrombosis (DVT) of the left popliteal vein. He is scheduled to begin chemotherapy in 2 days. Platelet count is 180 × 10⁹/L, and renal function is normal (eGFR 85 mL/min/1.73m²). Which anticoagulant is most appropriate for long-term management in this patient?

Explanation

## Cancer-Associated Thrombosis: Anticoagulation Strategy **Key Point:** Patients with cancer-associated venous thromboembolism (CAT) have higher recurrence rates and require prolonged anticoagulation with LMWH as first-line therapy, not warfarin or DOACs. ### Clinical Context - **Patient:** Metastatic pancreatic cancer (high thrombotic risk) - **Presentation:** Acute DVT of popliteal vein - **Renal function:** Normal (eGFR 85 mL/min/1.73m²) - **Platelet count:** Normal (180 × 10⁹/L) ### Why LMWH is Superior in Cancer-Associated VTE | Feature | LMWH | Warfarin | DOACs | UFH | |---------|------|----------|-------|-----| | **Recurrence rate in CAT** | Lower (preferred) | Higher | Higher than LMWH | Not for long-term | | **Mechanism** | Direct Xa inhibition | Vitamin K antagonist | Direct Xa/IIa inhibitors | Parenteral only | | **Interaction with cancer** | Minimal | Affected by liver metastases, drug interactions | Reduced bioavailability with GI dysfunction | Requires ICU monitoring | | **Bleeding risk** | Predictable | Unpredictable in cancer | Increased in GI malignancy | High with infusion | | **Recommendation in CAT** | **First-line** | Avoid | Avoid | Bridge only | **High-Yield:** ASCO and ACCP guidelines recommend LMWH for ≥3 months (or until cancer remission) in cancer-associated VTE. Warfarin and DOACs are inferior in this population. ### Mechanism: Why LMWH Works Better 1. **Direct Xa inhibition** — predictable anticoagulation 2. **Avoids liver metabolism** — important in metastatic disease 3. **No drug interactions** — critical during chemotherapy 4. **Anti-inflammatory and anti-cancer effects** — may reduce thrombotic recurrence **Clinical Pearl:** Pancreatic cancer is one of the highest thrombotic-risk malignancies. LMWH monotherapy is preferred over warfarin because: - Warfarin efficacy is reduced by liver involvement and drug interactions with chemotherapy - DOACs have reduced absorption with GI dysfunction and higher bleeding risk in GI malignancies - LMWH provides consistent anticoagulation independent of hepatic metabolism **Mnemonic:** **LMWH in CAT** — Low-Molecular-Weight Heparin is the standard for Cancer-Associated Thrombosis. ### Duration of Anticoagulation - **Minimum:** 3 months - **Optimal:** Until cancer remission or indefinitely if recurrent VTE - **Reassess:** Every 3 months for bleeding vs. thrombotic risk